THERACRYF PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.75 GBX | 0.00% |
|
0.00% | -53.12% |
| 04-26 | Evgen Pharma plc will Change its Ticker to TCF from EVG | CI |
| 04-26 | Evgen Pharma plc will Change its Name to TheraCryf plc | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 486K 664K | Sales 2025 * | - | Capitalization | 4.01M 5.48M |
|---|---|---|---|---|---|
| Net income 2024 * | -4M -5.47M | Net income 2025 * | - | EV / Sales 2024 * | 3.76 x |
| Net cash position 2024 * | 2.19M 2.99M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.59
x | P/E ratio 2025 * |
-
| Employees | 10 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.58% |
More Fundamentals
* Assessed data
More news
More press releases
| 3 months | -34.78% | ||
| 6 months | -58.33% | ||
| Current year | -53.12% |
1 week
0.72
0.79
1 month
0.700.85
Current year
0.702.00
1 year
0.704.00
3 years
0.709.50
5 years
0.7020.50
10 years
0.7045.00
| Managers | Title | Age | Since |
|---|---|---|---|
Huw Jones
CEO | Chief Executive Officer | 62 | - |
Toni Haenninen
DFI | Director of Finance/CFO | - | 23-09-04 |
Glen Clack
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Huw Jones
CEO | Chief Executive Officer | 62 | - |
Susan Foden
CHM | Chairman | 71 | 14-11-20 |
Alan Barge
BRD | Director/Board Member | - | 15-10-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.75 | 0.00% | 50,000 |
| 24-05-09 | 0.75 | 0.00% | 7,200 |
| 24-05-08 | 0.75 | 0.00% | 106,983 |
| 24-05-07 | 0.75 | 0.00% | 296,635 |
| 24-05-03 | 0.75 | 0.00% | 14,825 |
Delayed Quote London S.E., May 10, 2024 at 11:35 am
More quotes
Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage therapeutics company. The Company is engaged in developing a new generation of therapeutics in oncology and behavioral brain disorders. Its pipeline and lead compound SFX-01 is derived from its proprietary Sulforadex technology. Its Sulforadex technology synthesizes sulforaphane into an active, stable, and solid form pharmaceutical ingredient, unlocking its medical and commercial potential. SFX-01 is a complex of sulforaphane and alpha-cyclodextrin formulated as a stable tablet. The Company has a candidate orexin 1 antagonist at late preclinical stage targeting addictive behaviors. It also has a candidate molecule DAT inhibitor at late preclinical stage targeting fatigue and narcolepsy.
Calendar
2024-06-11
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -53.12% | 4.01M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- EVG Stock
